Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience (Q37484213)

20 August 2017

Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience (English)

1 reference

20 August 2017

Ricardo Cabanas

1

1 reference

20 August 2017

Giselle Saurez

2

1 reference

20 August 2017

Martha Rios

3

1 reference

20 August 2017

Jose Alert

4

1 reference

20 August 2017

Adnolys Reyes

5

1 reference

20 August 2017

Jose Valdes

6

1 reference

20 August 2017

Maria C Gonzalez

7

1 reference

20 August 2017

Jorge L Pedrayes

8

1 reference

20 August 2017

Melba Avila

9

1 reference

20 August 2017

Raiza Herrera

10

1 reference

20 August 2017

Mariela Infante

11

1 reference

20 August 2017

Ernesto Echevarria

12

1 reference

20 August 2017

Myrna Moreno

13

1 reference

20 August 2017

Patricia Lorenzo Luaces

14

1 reference

20 August 2017

Tania Crombet Ramos

15

1 reference

20 August 2017

1 March 2013

1 reference

20 August 2017

Monoclonal Antibodies

1 reference

20 August 2017

5

1 reference

20 August 2017

202-207

1 reference

20 August 2017

2

1 reference

Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Bevacizumab in recurrent high-grade pediatric gliomas

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Pediatric glioblastomas: a histopathological and molecular genetic study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Chemotherapy for malignant brain tumors of childhood.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Diffuse brainstem glioma in children: critical review of clinical trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Brain tumors in children--current therapies and newer directions

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Treatment of high-grade glioma in children and adolescents

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Epidermal growth factor receptor targeted therapies for solid tumours

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Nimotuzumab for pediatric diffuse intrinsic pontine gliomas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Cutaneous reactions to epidermal growth factor receptor inhibitors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Invasion is not an independent prognostic factor in high-grade glioma.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

[Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them].

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Tyrosine kinase expression in pediatric high grade astrocytoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893230

2 September 2018

Identifiers

DOI

10.4161/MABS.22970

1 reference

20 August 2017

1 reference

20 August 2017

1 reference